PROQR THERAPEUTICS NV (PRQR)

NL0010872495 - Common Stock

2.47  +0.09 (+3.78%)

News Image
15 days ago - ProQR Therapeutics N.V.

ProQR Announces Year End 2023 Operating and Financial Results

Preclinical and translational pipeline program data for AX-0810 for Cholestatic Diseases targeting NTCP and AX-1412 for Cardiovascular Disease targeting...

News Image
2 months ago - ProQR Therapeutics N.V.

ProQR Highlights New Platform Data from Presentation on Axiomer™ RNA Editing Technology at Deaminet 2024

Platform demonstrates robust in vivo editing capabilities reporting up to 70% editing of ACTB in the liver of non-human primates (NHPs) and miceFunctional...

News Image
2 months ago - Market News Video

Thursday Sector Laggards: Drugs, Water Utilities

News Image
3 months ago - ProQR Therapeutics N.V.

ProQR and Rett Syndrome Research Trust Join Forces with Axiomer™ RNA Editing Collaboration

Partnership focused on utilizing Axiomer™ to develop editing oligonucleotides targeting an underlying genetic variant that causes Rett...

News Image
4 months ago - ProQR Therapeutics N.V.

ProQR Therapeutics Announces Transaction Completed for Théa to Acquire Sepofarsen and Ultevursen Ophthalmic Assets

Divestment of sepofarsen and ultevursen completed – Théa to continue development of sepofarsen and ultevursen for patients with LCA10 and Usher syndrome ...

News Image
6 months ago - ProQR Therapeutics N.V.

ProQR Announces Participation in the Chardan 7th Annual Genetic Medicines Conference

LEIDEN, Netherlands & CAMBRIDGE, Mass., Sept. 28, 2023 (GLOBE NEWSWIRE) -- ProQR Therapeutics NV. (Nasdaq: PRQR) (ProQR), a company dedicated to...

News Image
6 months ago - ProQR Therapeutics N.V.

ProQR Therapeutics Provides Update on Ophthalmic Assets

News Image
7 months ago - ProQR Therapeutics N.V.

ProQR Announces Webcast of Presentation at the Upcoming HC Wainwright 25th Annual Global Investment Conference

LEIDEN, Netherlands & CAMBRIDGE, Mass., Sept. 07, 2023 (GLOBE NEWSWIRE) -- ProQR Therapeutics NV. (Nasdaq: PRQR) (ProQR), a company dedicated to...

News Image
8 months ago - ProQR Therapeutics N.V.

ProQR Announces Second Quarter 2023 Operating and Financial Results

Divestment of sepofarsen and ultevursen ophthalmic programs supports ProQR’s strategic focus on Axiomer® RNA editing platform technology and continued...

News Image
8 months ago - Seeking Alpha

ProQR stock gains on deal to divest eye disease therapies

ProQR Therapeutics (PRQR) traded higher Tuesday after announcing a deal with Laboratoires Théa to divest its RNA therapies sepofarsen and ultevursen. Read more here.

News Image
8 months ago - ProQR Therapeutics N.V.

ProQR Therapeutics and Laboratoires Théa Announce Agreement for Théa to Acquire ProQR’s Sepofarsen and Ultevursen Ophthalmic Assets

Agreement provides ProQR with initial payment of €12.5M and up to €135M in further payments, as well as potential additional earn outs based on commercial...

News Image
9 months ago - ProQR Therapeutics N.V.

ProQR to Present Data on its Axiomer® RNA Editing Technology at RNA Editing Summit

LEIDEN, Netherlands & CAMBRIDGE, Mass., July 06, 2023 (GLOBE NEWSWIRE) -- ProQR Therapeutics NV. (Nasdaq: PRQR) (ProQR), a company dedicated to...

News Image
a year ago - ProQR Therapeutics N.V.

ProQR to Present its Axiomer® RNA Editing Technology at TIDES USA 2023

LEIDEN, Netherlands & CAMBRIDGE, Mass., May 09, 2023 (GLOBE NEWSWIRE) -- ProQR Therapeutics NV. (Nasdaq: PRQR) (ProQR), a company dedicated to...

News Image
a year ago - ProQR Therapeutics N.V.

ProQR Announces Upcoming Investor Conferences in April and May

LEIDEN, Netherlands & CAMBRIDGE, Mass., April 20, 2023 (GLOBE NEWSWIRE) -- ProQR Therapeutics NV. (Nasdaq: PRQR) (ProQR), a company dedicated to...

News Image
a year ago - ProQR Therapeutics N.V.

ProQR Announces Annual Meeting of Shareholders to be Held May 17, 2023

LEIDEN, Netherlands & CAMBRIDGE, Mass., April 18, 2023 (GLOBE NEWSWIRE) -- ProQR Therapeutics NV. (Nasdaq: PRQR) (ProQR), a company dedicated to...